JANX
Janux Therapeutics Inc
16.30$
-2.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.2% | -49.1% | +610.6% | -95.1% | -2,039.0% | – | – | – | -21.2% | -52.6% | +175.0% | – | |
| – | +6.2% | +0.2% | -4.9% | +369.2% | +776.4% | +20.4% | +16.4% | -98.3% | +1,684.4% | -94.8% | – | – | |
| – | -4.3% | -62.7% | +1,065.4% | -123.1% | – | – | – | – | -111.2% | – | +214.6% | – | |
| – | +2.9% | +14.9% | +5.9% | +24.9% | +11.8% | +20.4% | +38.4% | -0.1% | -8.9% | -15.0% | +15.6% | – | |
| – | -1.3% | +15.5% | +6.5% | +125.9% | -53.5% | +19.8% | +6.2% | +1.6% | +2.2% | +2.6% | -1.5% | – | |
| – | +1.3% | +15.6% | +6.4% | +52.6% | -75.8% | +19.8% | +62.0% | +180.7% | -7.6% | -9.3% | +12.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -48.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.